Search

everythinglearnresearchcommunity

for

Search:↓

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Using electronic health records can help identify drug side effects but has some limitations.

Tofacitinib may help regrow hair in alopecia areata patients.

Men and patients on atypical antipsychotics have better mental functioning and quality of life.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Alefacept showed some effectiveness for alopecia areata but needs more research.

Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

A Taiwanese patient had hair loss and skin bumps without the usual gene mutation, suggesting other genetic factors might be involved.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Switching from escitalopram to duloxetine helped stop hair loss.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

A new HRAS gene variant may cause a range of symptoms including intellectual disability and psychiatric issues.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Diphenylcyclopropenone (DPCP) is effective in treating alopecia areata, with most patients showing significant hair regrowth.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.